Capitalization 4.52B 4.9B P/E ratio 2024 *
26.1x
P/E ratio 2025 * 21.6x
Enterprise value 3.25B 3.52B EV / Sales 2024 *
5.44x
EV / Sales 2025 * 4.81x
Free-Float
35.68%
Yield 2024 *
1.29%
Yield 2025 * 1.52%
More valuation ratios * Estimated data
Dynamic Chart

Last Transcript: Laboratorios Farmaceuticos Rovi, S.A.

1 day-0.74%
1 week+0.58%
Current month-0.40%
1 month+6.08%
3 months+8.39%
6 months+36.78%
Current year+44.85%
More quotes
1 week
84.50
Extreme 84.5
88.95
1 month
81.10
Extreme 81.1
88.95
Current year
60.35
Extreme 60.35
94.80
1 year
41.14
Extreme 41.14
94.80
3 years
35.20
Extreme 35.2
94.80
5 years
19.85
Extreme 19.85
94.80
10 years
7.90
Extreme 7.9
94.80
More quotes
Insider TitleAgeSince
Chief Executive Officer - 93-12-31
Director of Finance/CFO - 99-12-31
Chief Tech/Sci/R&D Officer - -
Insider TitleAgeSince
Chief Executive Officer - 93-12-31
Director/Board Member - 94-12-31
Director of Finance/CFO - 99-12-31
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
-0.74%+0.58%+107.62%+45.09% 4.94B
-2.10%-5.05%+87.21%+252.19% 791B
-2.16%-6.97%+62.71%+216.13% 595B
+2.58%-0.19%-8.65%-9.03% 367B
+1.24%+0.02%+15.75%+62.39% 315B
+1.77%+0.54%+23.07%+49.09% 306B
+0.07%+5.64%-0.40%-21.25% 247B
+0.20%+0.94%+13.41%+44.03% 244B
+0.08%-2.67%+5.47%+13.82% 218B
+0.71%-0.02%+42.56%+35.48% 179B
Average -0.36%-0.44%+34.87%+68.80% 326.65B
Weighted average by Cap. -0.56%-1.99%+39.07%+114.64%
See all sector performances
Ratios2024 *2025 *
Net sales 823M 892M 909M 986M
Net income 174M 188M 212M 230M
Net Debt -38.72M -41.96M -145M -157M
More financial data * Estimated data
Logo Laboratorios Farmaceuticos Rovi, S.A.
Laboratorios Farmaceuticos Rovi, S.A. specializes in the research, development, manufacturing and marketing of biological medications and specialty drugs. Net sales break down by family of products as follows: - pharmaceutical products manufactured under contract (49%); - prescription pharmaceuticals (45%): intended for preventing and treating venous thrombo-embolic disease, post-menopausal osteoporosis, muscle pain, tooth and mouth infections, angina, osteoarthritis, etc.; - diagnostic products (6%): contrast products used in medical imaging with magnetic resonance, ultrasound, or X-rays. The group also offers hospital products and non-prescription pharmaceuticals. Net sales break down by source of revenue between sales of products (50.6%), sales of services (49.3%) and sales of licenses (0.1%). Net sales are distributed geographically as follows: Spain (33%), European Union (17.3%), OECD countries (45.9%) and other (3.8%).
Employees
1,925
Related indices
More about the company
Date Price Change Volume
24-07-24 87.20 -0.74% 39,232
24-07-23 87.85 -0.17% 28,750
24-07-22 88.00 +3.77% 47,684
24-07-19 84.80 -0.35% 53,908
24-07-18 85.10 -1.05% 43,529

Delayed Quote BME, July 24, 2024 at 11:35 am EDT

More quotes
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
87.20EUR
Average target price
100.06EUR
Spread / Average Target
+14.75%
Consensus

Quarterly revenue - Rate of surprise